SEC Company Response from Aptose Biosciences Inc. (CIK 0000882361) (APTOF) — Dec 19, 2017
Aptose Biosciences Inc. (CIK 0000882361)
Date: Dec. 19, 2017 · CIK: 0000882361 · Accession: 0001193125-17-373765
AI Filing Summary & Sentiment
File numbers found in text: 333-221783
Letter
Re: Aptose Biosciences Inc. (the “Company”)
December 19, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Registration Statement on Form F-1 (File No. 333-221783)
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned respectfully requests that the effective date of the above-referenced registration statement be accelerated so that the same will become effective on December 21, 2017 at 5 PM EST, or soon thereafter as is practicable.
Very truly yours,
Aptose Biosciences Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP December 19, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Aptose Biosciences Inc. (the “Company”) Registration Statement on Form F-1 (File No. 333-221783) Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned respectfully requests that the effective date of the above-referenced registration statement be accelerated so that the same will become effective on December 21, 2017 at 5 PM EST, or soon thereafter as is practicable. Very truly yours, Aptose Biosciences Inc. By: /s/ William G. Rice Name: Title: William G. Rice, Ph.D. Chairman, President and Chief Executive Officer cc: Daniel M. Miller (Dorsey & Whitney LLP)